Oct 20, 2026 06:49AM
Oct 19, 2026 08:00AM
Oct 19, 2026 08:00AM
Jun 13, 2025 07:16AM
Jun 3, 2025 06:21AM
Jun 2, 2025 10:01AM
Jun 2, 2025 10:00AM UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
May 28, 2025 05:39AM
May 21, 2025 12:18PM
May 21, 2025 12:17PM
May 12, 2025 08:00AM
May 7, 2025 08:57AM
May 7, 2025 08:57AM
Apr 27, 2025 01:00PM New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC
Apr 27, 2025 12:30PM
Apr 26, 2025 06:30PM
Apr 14, 2025 08:00AM
Mar 10, 2025 08:00AM
Feb 14, 2025 02:30PM
Feb 14, 2025 02:30PM
Jan 15, 2025 08:05AM UroGen Pharma (URGN): ENVISION Trial Results Published in the February Issue of The Journal of Urology Highlight UGN-102 Achievement of 82.3% Duration of Response at 12 Months
Jan 15, 2025 08:00AM
Dec 5, 2024 03:22PM
Dec 5, 2024 03:15PM
Dec 2, 2024 08:00AM
Nov 6, 2024 08:00AM
Oct 15, 2024 04:31PM
Oct 15, 2024 04:30PM UroGen Announces FDA Acceptance of its New Drug Application for UGN-102
Aug 16, 2024 06:47AM
Mar 23, 2020 08:00AM
Mar 2, 2020 08:00AM
Jan 13, 2020 07:47AM
Dec 19, 2019 08:02AM
Dec 19, 2019 08:00AM

15,970 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All